AdvocacyRSS2 days ago
A patient with CIDP, a rare nerve disease that causes weakness and tingling, describes how much time the condition takes up each week—not just doctor visits, but also managing symptoms, doing physical therapy, and dealing with fatigue. The article shows that the real burden of living with CIDP goes beyond what doctors usually measure, including all the hidden time spent managing the disease day-to-day.
WHY IT MATTERSUnderstanding the time burden of CIDP helps patients feel less alone in their struggles and gives them language to explain to family, employers, and doctors why the disease affects their quality of life so much.
Clinical trialUNITERAREApr 3
Researchers are testing a medicine called IGIV 10% to see if it helps people with CIDP, a rare nerve disease that causes weakness and numbness, usually in the legs and feet. IGIV is made from antibodies collected from donated blood. This is a Phase 3 trial, which means the medicine has already been tested in earlier studies and now doctors want to confirm it works well and is safe.
WHY IT MATTERSThis Phase 3 trial is now actively recruiting patients with CIDP — if you have confirmed CIDP diagnosis, you may be eligible to access a potential new treatment option before it becomes widely available.